The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Depot fluphenazine decanoate and enanthate for schizophrenia
Open accessAbstract
BACKGROUND: In the years after the discovery of oral antipsychotic medications, it became clear that there was a link between stopping medication and relapse of psychotic symptoms. A series of long-acting preparations was developed. These depot preparations, are frequently used for those who find taking oral medication on a regular basis difficult or unacceptable. However, it has been a consistent concern that any reduction in relapse rate afforded by the depot preparations may be offset by an increase in undesirable side effects. There is one oral preparation and two depot forms (enanthate (Moditen) and decanoate (Modecate)). The decanoate form is more frequently used but both versions were reviewed in this work. OBJECTIVES: To compare depot fluphenazine medication to oral fluphenazine for treatment of schizophrenia. SEARCH STRATEGY: Electronic searches of Biological Abstracts, CSG's Register, EMBASE, LILACS, MEDLINE, PsycLIT, SCISEARCH, hand searching the references of all identified studies and contacting the manufacturers of the compounds. SELECTION CRITERIA: All randomised clinical trials that compared fluphenazine enanthate or fluphenazine decanoate to oral fluphenazine for people with schizophrenia or other psychoses were included. DATA COLLECTION AND ANALYSIS: One reviewer (CEA) inspected study citations and then the second reviewer (ME) independently inspected 20% of citations to ensure reliability. Full reports of the studies of agreed relevance were obtained and data extracted in the same manner by the authors. Trials were allocated to three quality categories, as described in the Cochrane Collaboration Handbook. Data were analysed on an intention-to-treat basis, and, where possible, parametric continuous data were presented. Tests for heterogeneity were undertaken. MAIN RESULTS: Data were very limited. There was no difference between fluphenazine hydrochloride and its depot form for outcomes such as global impression of functioning, relapse/re-hospitalisation, poor initial response to treatment, leaving the study early, depressed mood / suicide and side effects such as movement disorders, uncomfortable dry mouth, sleep problems and weight gain were equally common in both groups. Direct measures of mental state, social functioning and satisfaction with care were either not measured or presented in such as way as to make any analysis impossible. REVIEWER'S CONCLUSIONS: All six included studies relate to people with schizophrenia who are already stable on oral fluphenazine or seem contented to stay in the studies. How the data from this review relate to everyday psychiatric practices, where compliance with medication is more problematic, is debatable. The use of depot fluphenazine continues to be based on clinical judgement rather than evidence from methodical evaluation within trials. A large pragmatic randomized controlled trial is long overdue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten, A., Cooper, J. E., Day, R., & Bertelsen, A. (1992) · Psychological Medicine. Monograph Supplement · doi:10.1017/s0264180100000904 · Cited by 1,769
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Statistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
The unit of analysis error in studies about physicians' patient care behavior
Divine, G. W., Brown, J. T., & Frazier, L. M. (1992) · Journal of General Internal Medicine · doi:10.1007/bf02599201 · Cited by 749
Issues in the meta-analysis of cluster randomized trials
Donner, A., & Klar, N. (2002) · Statistics in Medicine · doi:10.1002/sim.1301 · Cited by 734
Low dose fluphenazine decanoate in maintenance treatment of schizophrenia
Kane, J. M., Rifkin, A., Quitkin, F., Nayak, D., Saraf, K., Ramos-Lorenzi, J. R., Klein, D. F., & Sachar, E. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90016-7 · Cited by 44
Cited by
Drug effects on salivary glands: dry mouth
Scully CBE, C. (2003) · Oral Diseases · doi:10.1034/j.1601-0825.2003.03967.x · Cited by 472
Leucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., & Leucht, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.020 · Cited by 419
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia
Adams, C. E., Fenton, M. K. P., Quraishi, S., & David, A. S. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.4.290 · Cited by 288
Self-citationA dverse D rug R eactions in the O rofacial R egion
Scully, C., & Bagan, J.-V. (2004) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130401500405 · Cited by 254
Packages of Care for Schizophrenia in Low- and Middle-Income Countries
Mari, J. D. J., Razzouk, D., Thara, R., Eaton, J., & Thornicroft, G. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000165 · Cited by 91
Metadata
- Authors
- David, A., Adams, C. E., Eisenbruch, M., Quraishi, S. N., & Rathbone, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2004-04-19
- Issue
- 1
- Pages
- CD000307-CD000307
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2401924872
- Cited by
- 194
- References
- 8
- Type
- reference entry
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Depot fluphenazine decanoate and enanthate for schizophrenia. https://app.cochat.ai/papers/10.1002/14651858.cd000307
- The paper
- David, A., Adams, C. E., Eisenbruch, M., Quraishi, S. N., & Rathbone, J. (2004). Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd000307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.